Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $134.30

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $134.30.

ORKA has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a report on Thursday, April 30th. Wedbush restated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Guggenheim reaffirmed a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th.

Oruka Therapeutics Price Performance

NASDAQ ORKA opened at $107.96 on Wednesday. Oruka Therapeutics has a 1 year low of $14.34 and a 1 year high of $115.51. The company has a market capitalization of $7.15 billion, a PE ratio of -53.18 and a beta of -0.34. The company has a fifty day moving average of $91.82 and a 200 day moving average of $65.45.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Research analysts expect that Oruka Therapeutics will post -2.27 earnings per share for the current year.

Insider Activity

In related news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 83,116 shares of company stock valued at $6,636,533. 23.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently modified their holdings of ORKA. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $28,000. Nykredit A S purchased a new position in Oruka Therapeutics during the second quarter worth approximately $29,000. BNP Paribas Financial Markets boosted its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.